Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome

Schnitzler's syndrome (SchS) is a rare, disabling, autoinflammatory disorder characterized by recurrent urticarial rash and monoclonal IgM gammopathy. Interleukin-1 beta (IL-1β) plays an important role in the pathophysiology of SchS. Only anecdotal reports demonstrate the efficiency and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorodetskiy, Vadim R., Salugina, Svetlana O., Fedorov, Evgeny S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925130/
https://www.ncbi.nlm.nih.gov/pubmed/29850358
http://dx.doi.org/10.1155/2018/5416907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925130/
https://www.ncbi.nlm.nih.gov/pubmed/29850358
http://dx.doi.org/10.1155/2018/5416907

Ejemplares similares